- QuidelOrtho Corporation, headquartered in San Diego, California, is a global leader in in vitro diagnostics, focusing on innovative medical products and equipment for laboratory testing and disease detection.
- In February 2026, QuidelOrtho entered a strategic supply agreement with Lifotronic Technology Co., Ltd. to expand its global immunoassay portfolio, adding over 25 new assays to its offerings.
- The company reported total revenue of $724 million for FY 2025, with significant growth in its Labs and TRIAGE™ segments, and anticipates improved free cash flow exceeding $200 million in 2026.
- QuidelOrtho's ideal buyers include laboratories and healthcare providers seeking high-quality, cost-efficient diagnostic solutions, particularly in light of their recent expansion into new assay platforms and markets.
QuidelOrtho's workforce is organized into six departments, with the Executive team comprising the largest segment at five employees. The Information Technology department follows with three employees, while the Legal department has two. Other departments, including Engineering and Operations, each have one employee, contributing to a diverse functional mix. The presence of 14 employees in 'Other' indicates a variety of specialized roles that support the core operations of the company.
The company's workforce is distributed across nine locations, with the largest concentration in San Diego, CA, housing six employees. Raritan, NJ, and New York, NY, follow with three and two employees, respectively. The remaining locations, including Dallas, TX, and several others, each have one employee, reflecting a decentralized approach. The 'Other' category, which includes nine additional locations, suggests a broad geographic footprint that supports operational flexibility.
